New hope for advanced liver cancer patients in groundbreaking trial
NCT ID NCT07175441
Summary
This study is testing whether adding a new drug called RBS2418 to an existing immunotherapy combination works better for people with advanced liver cancer that cannot be removed by surgery. About 220 participants will receive either the standard immunotherapy alone or the standard immunotherapy plus RBS2418. The main goal is to see if the new combination helps control the cancer for longer without it getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins
RECRUITINGBaltimore, Maryland, 21218, United States
-
START Dallas Fort Worth
RECRUITINGFort Worth, Texas, 76104, United States
-
Vanderbilt-Ingram Cancer Center
RECRUITINGNashville, Tennessee, 37232, United States
Conditions
Explore the condition pages connected to this study.